EP
SAGE

Essential Partners’s Sage Therapeutics SAGE Stock Holding History

Essential Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,924
Closed -$54K – 2769
2025
Q2 		$54K Buy
+5,924
New +$43.6K 0.02% 457

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Essential Partners's SAGE Position: Q3 2025 in Review

Essential Partners sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 5,924 shares — an estimated $54K sold.

Essential Partners first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $54K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Essential Partners reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 5,924 Sage Therapeutics shares in Q3 2025, an estimated $54K.
  • Essential Partners first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Sage Therapeutics position peaked at $54K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.